99 completed, 72 recruiting, 36 unknown, 24 terminated. 63 Phase 2, 48 Phase 1, 42 Phase 3, 26 Phase 4, 21 Not applicable.
Follow Systemic Vasculitis: new trials by email Literature Review of Systemic Vasculitis trials Research Report on Systemic Vasculitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases CD19-targeted iNKT Cell Injection - IgA Nephropathy (IgAN), Membranous Nephropathy | Early Phase 1 | Not yet recruiting | Grit Biotechnology | 30 | 2027-08-01 | 2026-09-11 |
| Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined With Immunosuppressants in the Treatment of Refractory Autoimmune Diseases anti-CD19 CAR-T cells - Systemic Lupus Erthematosus, Systemic Sclerosis (SSc) | Phase 1 / Phase 2 | Not yet recruiting | Peking University Third Hospital | 9 | 2026-11-01 | 2026-09-23 |
| Qualitative Study With Focus Groups of People Living With ANCA-associated Vasculitis (AAV) and Clinicians, to Explore Different Perspectives on Shared Decision-making in AAV. ANCA Associated Vasculitis (AAV) | Not yet recruiting | University of the West of England | 80 | 2026-10-01 | 2026-10-06 | |
| FT839 in Autoimmune Diseases FT839 - ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM) | Phase 1 / Phase 2 | Recruiting | Fate Therapeutics | 446 | 2026-10-01 | 2026-09-02 |
| MYTP01 for Immune-Mediated Diseases MYTP01, MYTP01 Placebo - IgA Nephropathy, Kidney Transplant Recipients | Not applicable | Not yet recruiting | Zhejiang Provincial People's Hospital | 160 | 2026-10-01 | 2026-10-28 |
| Inflammatory Disease Biobank for Immunophenotyping and Cardiovascular Research Pericarditis, Tako-TSUBO Cardiomyopathy | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 300 | 2026-09-01 | 2026-08-10 | |
| CD19/BCMA-Targeted Universal CAR-T Cell Injection for the Treatment of Autoimmune Diseases RD06-05 CAR-T Cell Injection - SLE - Systemic Lupus Erythematosus, Systemic Sclerosis | Early Phase 1 | Not yet recruiting | Nanjing Bioheng Biotech Co., Ltd. | 30 | 2026-09-01 | 2026-07-16 |
| Obinutuzumab Beta Combined With Low-dose Glucocorticoid in New-onset ANCA-Associated Glomerulonephritis Obinutuzumab beta, Glucocorticoids - ANCA-Associated Glomerulonephritis (AAGN), ANCA-Associated Vasculitis (AAV) | Phase 2 | Recruiting | Chinese PLA General Hospital | 20 | 2026-08-21 | 2026-09-15 |
| Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment Benralizumab - Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA) | Phase 3 | Recruiting | AstraZeneca | 230 | 2026-07-24 | 2026-10-27 |
| Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases Allogeneic CD19/BCMA-targeted CAR-γδT cell injection, Cyclophosphamide, Fludarabine - Refractory/Relapsed Systemic Lupus Erythematosus, Refractory / Relapsed / Progressive Systemic Sclerosis | Phase 1 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 9 | 2026-07-01 | 2026-06-09 |
| Study of NM8074 in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV) NM8074, Placebo - Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Phase 2 | Not yet recruiting | NovelMed Therapeutics | 12 | 2026-06-01 | 2025-03-11 |
| TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With Polyangiitis Avacopan, Placebo - Granulomatosis With Polyangiitis, Wegener's | Phase 2 / Phase 3 | Recruiting | Robert Spiera, MD | 30 | 2026-05-22 | 2026-09-02 |
| Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease UCAR T-cell - Autoimmune Diseases, Systemic Lupus Erthematosus (SLE) | Early Phase 1 | Recruiting | The Children's Hospital of Zhejiang University School of Medicine | 15 | 2026-04-01 | 2026-04-02 |
| CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis CC-97540, Lymphodepletion Chemotherapy - Antineutrophil Cytoplasmic Antibody-associated Vasculitis | Phase 1 / Phase 2 | Active not recruiting | Marcela V. Maus, M.D.,Ph.D. | 12 | 2026-03-30 | 2026-09-10 |
| MTS109 in Patients With Refractory Autoimmune Diseases MTS109 - Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies | Early Phase 1 | Recruiting | Shanghai Changzheng Hospital | 15 | 2026-03-24 | 2026-06-30 |
| Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases Dengue 1,2,3,4 (attenuated) vaccine - Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA) | Phase 4 | Recruiting | University of Sao Paulo General Hospital | 477 | 2026-03-16 | 2026-07-20 |
| Avacopan Added to Standard-of-care Therapy in ANCA-associated Vasculitis With Severe Kidney Involvement Avacopan, Placebo - ANCA-Associated Vasculitis (AAV) | Phase 3 | Not yet recruiting | University Hospital, Toulouse | 130 | 2026-03-01 | 2026-01-28 |
| YTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases YTS109 cell - Systemic Lupus Erythematosus (SLE), Diffuse Systemic Sclerosis | Phase 1 | Not yet recruiting | Children's Hospital of Fudan University | 12 | 2026-03-01 | 2026-02-27 |
| Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases anti-CD19/BCMA U CAR T cells - Autoimmune Diseases, Systemic Lupus Erythematosus | Early Phase 1 | Recruiting | Changhai Hospital | 60 | 2026-02-20 | 2026-02-25 |
| Benralizumab Effectiveness in EGPA Benralizumab 30 mg/ml - Eosinophilic Granulomatosis With Polyangiitis (EGPA) | Recruiting | European EGPA Study Group | 100 | 2026-02-11 | 2026-09-11 |
Showing 20 of 279. Sign in to see all of them.
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (154) · Granulomatosis with Polyangiitis (104) · Microscopic Polyangiitis (69) · Vasculitis (63) · Churg-Strauss Syndrome (61) · Lupus Erythematosus, Systemic (49) · Scleroderma, Systemic (44) · Myositis (40) · Sjogren's Syndrome (24) · Takayasu Arteritis (24) · Arthritis, Rheumatoid (22) · Giant Cell Arteritis (22) · Polyarteritis Nodosa (22) · Antiphospholipid Syndrome (18)
Skin and Connective Tissue Diseases (278) · Cardiovascular Diseases (274) · Skin Diseases (274) · Vascular Diseases (273) · Skin Diseases, Vascular (271) · Immune System Diseases (269) · Autoimmune Diseases (253) · Vasculitis (216) · Nervous System Diseases (121) · Respiratory Tract Diseases (115) · Lung Diseases (113) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (106) · Lung Diseases, Interstitial (104) · Central Nervous System Diseases (82)
Rituximab (36) · Cyclophosphamide (31) · Azathioprine (21) · Prednisone (19) · mepolizumab (14) · Glucocorticoids (12) · avacopan (12) · Mycophenolic Acid (9) · Methylprednisolone (8) · fludarabine (8) · Blood Specimen Collection (7) · Methotrexate (7) · Prednisolone (6) · Abatacept (4) · Infliximab (4)
Assistance Publique - Hôpitaux de Paris (28) · National Institute of Allergy and Infectious Diseases (NIAID) (13) · University of Pennsylvania (13) · Amgen (9) · Cambridge University Hospitals NHS Foundation Trust (7) · University of South Florida (7) · China Immunotech (Beijing) Biotechnology Co., Ltd. (6) · GlaxoSmithKline (6) · Nanjing Bioheng Biotech Co., Ltd. (6) · AstraZeneca (4) · Institute of Hematology & Blood Diseases Hospital, China (4) · Chinese SLE Treatment And Research Group (3) · Hospices Civils de Lyon (3) · Peking University Third Hospital (3) · Staidson (Beijing) Biopharmaceuticals Co., Ltd (3)
United States (92) · China (62) · France (58) · United Kingdom (44) · Canada (31) · Germany (25) · Italy (21) · Japan (16) · Netherlands (15) · Belgium (10) · Brazil (10) · Czechia (10) · Poland (10) · Sweden (10) · Australia (9)
Peter A. Merkel, MD, MPH (10) · Peter A Merkel, MD, MPH (8) · David Jayne (4) · Amanda M. Terry, MA (3) · Loic Guillevin, MD, PhD (3) · Peter Merkel, MD, MPH (3) · David Jayne, MD (2) · Fernando C. Fervenza, M.D., Ph.D. (2) · Jeffrey P Krischer, PhD (2) · John H. Stone, MD, MPH (2) · Juhong Shi, M.D (2)
PMID 33164993, PMID 28514601, PMID 25153486, PMID 25372085, PMID 28592297, PMID 31719529, PMID 33001543, PMID 33596356, PMID 34061144, PMID 34347947, PMID 35612893, PMID 35850947, PMID 36927642, PMID 37161084, PMID 38251561, PMID 38393328, PMID 39425055, PMID 11786196, PMID 12905485, PMID 15751091, PMID 15838068, PMID 15986348, PMID 16142864, PMID 16378799, PMID 16646004, PMID 16914703, PMID 16987829, PMID 16996579, PMID 17407214, PMID 17471524, PMID 17557758, PMID 18163506, PMID 18240234, PMID 19054820, PMID 19109574, PMID 19451574, PMID 20093349, PMID 20360188, PMID 20647199, PMID 21060104, PMID 21109517, PMID 21325353, PMID 21540203, PMID 21859696, PMID 21954229, PMID 2202307, PMID 22089462, PMID 22127969, PMID 22298793, PMID 22908326
U54AR057319 (8), 2023 (5), 2016 (3), P01DK058335 (3), 2009 (2), 2018 (2), 2025 (2), R01HL115041 (2), 2014 (1), 2015 (1), 2017 (1), 2019 (1), R01HD066139 (1), UL1RR024150 (1)